Rapamycin is the most talked-about longevity drug that almost nobody is actually taking. It extends lifespan in nearly every organism tested — yeast, worms, flies, mice — by 10-25% depending on the species. The question that matters is whether any of that translates to humans.
The PEARL trial is the closest thing we have to an answer so far. And what it found is more nuanced than either the skeptics or the evangelists want to admit.
What Is Rapamycin?
Rapamycin (sirolimus) was originally discovered in soil bacteria from Easter Island — Rapa Nui in the indigenous language, which gave the compound its name. It was developed as an immunosuppressant for organ transplant recipients and later approved for use in drug-eluting cardiac stents.
The longevity connection emerged when researchers at the National Institute on Aging's Interventions Testing Program found that rapamycin extended lifespan in genetically diverse mice — even when started late in life. That was 2009. The finding was replicated, expanded, and the longevity research community has been wrestling with how to translate it ever since.
The mechanism centers on mTOR (mechanistic target of rapamycin), a nutrient-sensing pathway that regulates cell growth, protein synthesis, and autophagy. When nutrients are abundant, mTOR drives growth. When it's inhibited — by fasting, caloric restriction, or rapamycin — the cell shifts toward maintenance and repair.
mTOR inhibition is believed to mimic the cellular effects of caloric restriction, which is the most consistently replicated longevity intervention across species. Rapamycin may achieve a similar metabolic shift without requiring you to eat 30% fewer calories indefinitely.
The PEARL Trial: Design and Results
The Participatory Evaluation of Aging with Rapamycin for Longevity (PEARL) trial enrolled 114 generally healthy adults aged 50-85. Participants received either low-dose rapamycin (5 mg or 10 mg weekly) or placebo for 48 weeks. This was the first randomized, placebo-controlled trial designed specifically to study rapamycin's effects on age-related outcomes in healthy older adults.
What They Measured
The primary endpoints focused on age-related biomarkers:
- Visceral fat changes via DEXA scan
- Bone mineral density changes
- Blood biomarkers including fasting glucose, lipid panels, and inflammatory markers
- Immune function assessments
- Adverse event tracking throughout the 48-week period
Key Findings
Body composition: Rapamycin did not produce statistically significant changes in visceral fat or lean mass compared to placebo over 48 weeks. This was one of the primary endpoints, and the null result is important — it suggests that at these doses, rapamycin is not dramatically reshaping body composition in the short term.
Bone density: No significant bone loss was observed in the rapamycin groups, which was a relief. At higher immunosuppressive doses used in transplant medicine, rapamycin has been associated with reduced bone density. The low weekly dosing schedule used in PEARL did not produce this effect.
Lipids and metabolic markers: Some participants in the rapamycin groups showed transient increases in triglycerides and LDL cholesterol, consistent with known mTOR inhibitor effects on lipid metabolism. These changes were generally mild and reversible.
Immune markers: This may be the most interesting finding. Prior work by Joan Mannick at Novartis (published in Science Translational Medicine) showed that low-dose mTOR inhibition in older adults actually improved immune function — measured by response to influenza vaccination. The PEARL data added to the evidence that intermittent, low-dose rapamycin does not cause clinically meaningful immunosuppression.
Safety: Rapamycin was generally well tolerated. The most common side effects were mouth sores (aphthous ulcers), which occurred in a subset of participants and were typically mild and self-limiting. No serious infections or major adverse events were attributed to the drug.
Related: If you're tracking your own aging biomarkers, check out Biological Age Testing: Which Predicts Lifespan? and The Blood Panel Every Biohacker Should Run.
Oxford Senescent Cell Research
While the PEARL trial examined rapamycin's systemic effects, parallel research at the University of Oxford has been exploring how rapamycin affects senescent cells — the damaged, non-dividing cells that accumulate with age and secrete inflammatory compounds (the senescence-associated secretory phenotype, or SASP).
In preclinical models, rapamycin has been shown to reduce the SASP burden rather than clearing senescent cells outright. This is a mechanistic distinction that matters: senolytics aim to kill senescent cells, while rapamycin may suppress their harmful secretions while leaving them in place.
Oxford researchers have demonstrated that mTOR inhibition can reduce the inflammatory output of senescent cells in human tissue models. The working hypothesis is that rapamycin's longevity effects may operate partly through this pathway — reducing chronic inflammation driven by accumulated senescent cells without the risks of outright cellular clearance.
This is still early-stage research. The senescent cell mechanism is one of several proposed explanations for rapamycin's longevity effects, alongside autophagy induction, stem cell rejuvenation, and metabolic reprogramming. No single mechanism has been confirmed as the primary driver in humans.
Side Effects: What the Data Actually Shows
The side effect profile of rapamycin depends heavily on dose and schedule. At transplant-level doses (daily, 2-5 mg), the side effect list is substantial: immunosuppression, hyperlipidemia, impaired wound healing, mouth ulcers, insulin resistance, and potential fertility effects.
At the intermittent low doses used in longevity protocols (typically 3-6 mg once weekly), the side effect profile is markedly different:
Mouth sores (most common): Aphthous ulcers appear in roughly 20-30% of users at longevity doses. They're typically mild, resolve on their own, and many practitioners address them with dose adjustments. Some users report they diminish after the first few months.
Lipid changes: Transient increases in triglycerides and LDL are documented. Longevity physicians typically monitor lipid panels every 3-6 months and adjust dosing if changes are clinically significant.
Blood glucose: Some users experience mild fasting glucose elevation. At weekly dosing, this effect appears less pronounced than at daily dosing. Monitoring is standard practice.
Immunosuppression: At weekly low doses, clinically significant immunosuppression has not been demonstrated. The Mannick studies actually showed improved immune response. However, most longevity physicians recommend pausing rapamycin before elective surgeries or during active infections.
Wound healing: Rapamycin can impair wound healing. Users should discontinue use before scheduled procedures. This is well-documented at transplant doses and theoretically relevant at lower doses as well.
Rapamycin is a prescription medication with real pharmacological effects. It should not be obtained without a physician's oversight, and regular monitoring of blood work — including lipid panels, fasting glucose, and CBC — is a non-negotiable part of responsible use.
Off-Label Prescribing: The Current Landscape
Rapamycin is not FDA-approved for longevity or anti-aging. Physicians who prescribe it for this purpose are doing so off-label — a legal practice in the United States, but one that requires clinical judgment and informed consent.
The prescribing landscape has evolved considerably since 2020:
Longevity clinics: A growing number of longevity-focused practices now include rapamycin in their toolkit. Organizations like the American Academy of Anti-Aging Medicine (A4M) have featured rapamycin discussions at recent conferences.
Typical protocols: Most longevity physicians prescribe 3-6 mg weekly (sometimes biweekly), often cycling on and off (8 weeks on, 4 weeks off is a common approach). Some use grapefruit juice to boost bioavailability, as compounds in grapefruit inhibit the CYP3A4 enzyme that metabolizes rapamycin.
Cost: Generic sirolimus is relatively affordable — typically $30-80/month at longevity doses. The primary cost barriers are the physician visits, lab work, and monitoring that responsible use requires.
Who is prescribing: Board-certified physicians with backgrounds in internal medicine, endocrinology, or gerontology. The field is self-regulating at this point, which means quality varies significantly between practitioners.
What We Still Don't Know
The PEARL trial was 48 weeks with 114 participants. That is valuable but limited:
- We don't know if low-dose rapamycin extends human lifespan. That trial would take decades and has never been funded.
- We don't know the optimal dose and schedule for longevity purposes. Current protocols are educated guesses based on animal data and clinical experience.
- We don't know who benefits most. Age, metabolic status, genetic background, and existing health conditions may all influence response.
- We don't know the long-term safety profile of decades of intermittent use. The transplant data covers chronic daily dosing, which is a different exposure profile.
- We don't know how rapamycin interacts with other longevity interventions (metformin, NAD+ precursors, senolytic protocols).
The Practical Question
Should you take rapamycin for longevity? The honest answer: the evidence is among the most promising for any single longevity compound, but human data remains insufficient to make a confident recommendation.
What the PEARL trial established is that low-dose intermittent rapamycin appears to be reasonably well-tolerated in healthy older adults over 48 weeks. That's a necessary foundation, but it's not the same as demonstrating benefit.
If you're considering rapamycin, the minimum responsible approach includes:
- Working with a physician experienced in longevity medicine
- Baseline and regular monitoring of lipids, fasting glucose, CBC, and liver function
- Understanding that you are participating in an informal experiment on yourself
- Having a clear protocol for pausing or discontinuing if side effects emerge
- Not combining with immunosuppressive medications or in the setting of active infection
The science is moving. Larger and longer trials are in planning and recruitment phases. In the meantime, rapamycin sits in an unusual position: the most compelling longevity candidate in animal models, with human safety data that's growing but not yet definitive.
Be the first to try Prova
We're building an app to track whether rapamycin and longevity biomarker tracking actually works. Join the waitlist.